Allarity Therapeutics Inc
Research Allarity Therapeutics Inc (ALLR) on Bullrun: market cap USD 21.16M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALLR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 21.16M
- Financial periodQ1 2026
- RevenueUSD 25.00K
- Net income-USD 2.75M
- Free cash flow-USD 4.56M
Valuation Snapshot
latest market cap is USD 21.16M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 320.00K | -USD 11.23M | -USD 14.83M | n/a | -1.37 | USD 14.69M | USD 0 | USD 9.83M |
| FY2024 | USD 0 | -USD 24.52M | -USD 17.65M | n/a | -690.86 | USD 19.53M | USD 1.35M | USD 11.81M |
| FY2023 | n/a | -USD 11.90M | -USD 12.75M | n/a | -10.26 | USD 166.00K | USD 2.94M | -USD 2.75M |
| FY2022 | n/a | -USD 16.06M | -USD 16.84M | n/a | -3093.42 | USD 2.03M | USD 2.64M | -USD 113.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 21.16M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 17.37M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.54M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.24M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 148.18M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.61B | n/a | n/a | n/a |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Allarity Therapeutics Inc's market cap?
Allarity Therapeutics Inc's market capitalization is USD 21.16M.
What does Allarity Therapeutics Inc do?
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer.